Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Details : Novartis India Limited enters into an exclusive sales and distribution agreement with Dr. Reddy’s Laboratories for a few of its Established Medicines which includes the Voveran® range, the Calcium range and Methergine®.
Product Name : Voveran
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 02, 2022
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : NBCD
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 18, 2024
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : NBCD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparative Evaluation of Sustained Acoustic Medicine Device on Circulation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2024
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Chromocell Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Benuvia Operations and Chromocell Form Strategic Partnership for Healthcare Solutions
Details : The partnership grants Chromocell access to concentrate on the clinical advancement of a sublingual formulation of a Diclofenac spray designed for treating acute pain.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 27, 2024
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Chromocell Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2024
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Knee Pain Related to Osteoarthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Diclofenac Gel in Women With Primary Dysmenorrhea
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 02, 2023
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Diclofenac hydrogel patches are a nonsteroidal anti-inflammatory drug (NSAIDs) products that are used to treat short-term pain due to minor strains, sprains and bruises.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2022
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : IND Enabling
Sponsor : Kindeva Drug Delivery
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Epoladerm™ (diclofenac epolamine), an investigational analgesic supplied in a pre-filled device for administration as a topical spray film to manage chronic pain associated with osteoarthritis of the knee.
Product Name : Epoladerm
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2022
Lead Product(s) : Diclofenac,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : IND Enabling
Sponsor : Kindeva Drug Delivery
Deal Size : Inapplicable
Deal Type : Inapplicable